Know Cancer

forgot password

An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage

Phase 2
18 Years
Not Enrolling
Leukemia, Myeloid, Acute

Thank you

Trial Information

An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and
efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to
subjects with AML. The study will primarily assess the complete response (CR) rate of a
5-day continuous infusion of troxacitabine at 12 mg/m2/day given as second salvage therapy
in adult patients with AML, with secondary objectives to determine the overall, relapse-free
and event-free survival and remission duration; to determine the duration of response; to
determine the complete response with incomplete platelet recovery (CRp) rate; to evaluate
the tolerability and safety of 5-day continuous intravenous (IV) infusion of troxacitabine;
and to determine the relationship between troxacitabine plasma concentrations, anti-leukemic
activity and adverse events. Additional cycles of treatment may be given at the
investigator’s discretion, provided that the subject does not have progressive disease or
experience a dose limiting toxicity. Bone marrow transplantation in responding subjects will
be allowed.

Inclusion Criteria:

- Confirmed diagnosis of acute myeloid leukemia (AML) in the second salvage setting:
refractory to two prior courses of therapy or primary refractory without response to
two previous courses of leukemia therapy.

- Patients must have received at least two previous courses of induction chemotherapy
to be considered in the second salvage setting.

- Patients who are in second relapse, must have had a duration of their second CR or
CRp of less than six months.

- Subjects must have adequate organ and immune function as indicated by the following
laboratory values:

- Creatinine clearance ≥ 45 mL/min and ≤ 125 mL/min;

- Total bilirubin ≤ 2.0 mg/dL (≤ 34.2 µmol/L);

- AST (SGOT) and ALT (SGPT) ≤ 3 x upper limit of normal (ULN).

- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance
status of < 2, and an estimated life expectancy of at least eight weeks.

Exclusion Criteria:

- Clinical evidence of active central nervous system (CNS) leukemic involvement

- Active and uncontrolled infection

- Uncontrolled medical problems unrelated to the malignancy that impair patient ability
to give informed consent or unacceptably reduce the safety of the proposed treatment

- Neurologic or psychiatric disorders that would interfere with informed consent or
study follow-up

- Known or suspected intolerance or hypersensitivity to Troxatyl® or closely related
compounds such as lamivudine or any of the stated ingredients

- A recent history of alcohol or other substance abuse

- Subjects who have used another investigational agent or participated in a clinical
trial within the last 14 days prior to enrolment

- Females with a positive pregnancy test at screening

- Subjects who have previously been enrolled into this study and subsequently withdrew

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine complete response (CR) rate

Principal Investigator

Francis Giles, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2005

Completion Date:

October 2007

Related Keywords:

  • Leukemia, Myeloid, Acute
  • Acute myeloid leukemia
  • AML
  • refractory
  • relapsed
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid



Cleveland Clinic Foundation Cleveland, Ohio  44195
Roswell Park Cancer Institute Buffalo, New York  14263
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Washington University School of Medicine Saint Louis, Missouri  63110
Loyola University Medical Center Maywood, Illinois  60153
Scripps Clinic La Jolla, California  92037
Morgantown Internal Medicine Group Morgantown, West Virginia  26505
Dana Farber Cancer Institute Boston, Massachusetts  02115
University of Chicago Chicago, Illinois  60637
UCSD Moores Cancer Center La Jolla, California  93093
USC-Norris Neuro-Oncology Program Los Angeles, California  90033
Univ. of Florida, Baptist Cancer Center Jacksonville, Florida  32209
Winship Cancer Institute, Emory University Hosp. Atlanta, Georgia  30322
Harper Hospital - Karmanos Cancer Center Detroit, Michigan  48201
Univ. of Minnesota Medical Center Minneapolis, Minnesota  55455
New York Presbyterian Hospital-Cornell Campus New York, New York  10021
Wake Forest Univ. School of Medicine Winston-Salem, North Carolina  27157
Univ. of South Carolina, Hematology/Oncology Division Charleston, South Carolina  29425
Univ. of Texas, MD Anderson Cancer Center Houston, Texas  77030
University of Utah Huntsman Cancer Institute Salt Lake City, Utah  84112